BI 695500

DRUG4 trials

Sponsors

Boehringer Ingelheim

Conditions

Arthritis, RheumatoidLymphoma, FollicularLymphoma, Non-Hodgkin

Phase 1

Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab as First Line-treatment in Patients With Low Tumor Burden Follicular Lymphoma

CompletedNCT01950273

Boehringer IngelheimLymphoma, Follicular

Start: 2013-09-27End: 2015-12-22Updated: 2018-09-05

Phase 3

Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis

TerminatedNCT01682512

Boehringer IngelheimArthritis, Rheumatoid

Start: 2012-09-05End: 2016-10-12Updated: 2018-01-30

Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis

TerminatedNCT01955733

Boehringer IngelheimArthritis, Rheumatoid

Start: 2013-05-31End: 2016-11-07Updated: 2018-01-18

BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma

TerminatedNCT02417129

Boehringer IngelheimLymphoma, Non-Hodgkin

Start: 2015-04-30End: 2015-12-31Updated: 2017-01-30